Psoriatic arthritis (PsA) is a chronic immune-mediated disease characterized by psoriatic skin and nail changes, peripheral joint inflammation, enthesitis, dactylitis, and/or axial involvement, either alone or in combination with each other. The presence of axial involvement has been shown to be a marker of PsA severity; however, there is no widely accepted definition of axial involvement in PsA (axPsA) or consensus on how or when to screen and treat patients with suspected axPsA. Chronic back pain is a prominent feature of axPsA and is thought to have a relevant role in early identification of disease. Chronic back pain can be caused by inflammatory back pain (IBP) or mechanical back pain (MBP). However, MBP can complicate recognition of IBP and Digital Features To view digital features for this article go to

Objective A treat‐to‐target (TTT) approach improves outcomes in rheumatoid arthritis (RA). In prior work, we found that a learning collaborative (LC) program improved implementation of TTT. We conducted a shorter virtual LC to assess the feasibility and effectiveness of this model for quality improvement and to assess TTT during virtual visits. Methods We tested a 6‐month virtual LC in ambulatory care. The LC was conducted during the 2020–2021 COVID‐19 pandemic when many patient visits were conducted virtually. All LC meetings used videoconferencing and a website to share data. The LC comprised a 6‐hour kickoff session and 6 monthly webinars. The LC discussed TTT in RA, its rationale, and rapid cycle improvement as a method for implementing TTT. Practices provided de‐identified patient visit data. Monthly webinars reinforced topics and demonstrated data on TTT adherence. This was measured as the percentage of TTT processes completed. We compared TTT adherence between in‐person visits versus virtual visits. Results Eighteen sites participated in the LC, representing 45 rheumatology clinicians. Sites inputted data on 1,826 patient visits, 78% of which were conducted in‐person and 22% of which were held in a virtual setting. Adherence with TTT improved from a mean of 51% at baseline to 84% at month 6 (P for trend < 0.001). Each aspect of TTT also improved. Adherence with TTT during virtual visits was lower (65%) than during in‐person visits (79%) (P < 0.0001). Conclusion Implementation of TTT for RA can be improved through a relatively low‐cost virtual LC. This improvement in TTT implementation was observed despite the COVID‐19 pandemic, but we did observe differences in TTT adherence between in‐person visits and virtual visits.

No abstract

s201were from all regions of the United States (Northeast, 19.3%; North Central, 15.7%; South, 44.7%; West, 16.1%; Puerto Rico/Virgin Islands, 0.4%); approximately 60% of patients were female and the mean (SD) age was 53.6 (12.0) years. Overall, 6.1% of patients were biologic naive, 41.9% received ≥ 1 prior biologic therapy, and 52.0% had missing information about prior biologic use. Among patients with prior biologic use, 38.6% had 1 reported biologic efficacy failure, 33.8% had 2 efficacy failures, and 27.7% had ≥ 3 efficacy failures; the most commonly reported biologic efficacy failures were adalimumab (67.4%) and etanercept (59.1%). For both initial and maintenance dosing, approximately half of patients were prescribed secukinumab 300 mg (51.1% and 51.6%, respectively). ConClusions: In this analysis of SRFs filled by patients with PsA and their health care providers, approximately half of patients were prescribed secukinumab 300 mg for both initial and maintenance dosing. These results provide early insights into the prescribing patterns of secukinumab for PsA in a US real-world setting. Future research is needed to better understand how clinical characteristics and treatment history may affect secukinumab usage in US patients with PsA.

s201were from all regions of the United States (Northeast, 19.3%; North Central, 15.7%; South, 44.7%; West, 16.1%; Puerto Rico/Virgin Islands, 0.4%); approximately 60% of patients were female and the mean (SD) age was 53.6 (12.0) years. Overall, 6.1% of patients were biologic naive, 41.9% received ≥ 1 prior biologic therapy, and 52.0% had missing information about prior biologic use. Among patients with prior biologic use, 38.6% had 1 reported biologic efficacy failure, 33.8% had 2 efficacy failures, and 27.7% had ≥ 3 efficacy failures; the most commonly reported biologic efficacy failures were adalimumab (67.4%) and etanercept (59.1%). For both initial and maintenance dosing, approximately half of patients were prescribed secukinumab 300 mg (51.1% and 51.6%, respectively). ConClusions: In this analysis of SRFs filled by patients with PsA and their health care providers, approximately half of patients were prescribed secukinumab 300 mg for both initial and maintenance dosing. These results provide early insights into the prescribing patterns of secukinumab for PsA in a US real-world setting. Future research is needed to better understand how clinical characteristics and treatment history may affect secukinumab usage in US patients with PsA.